FY2024 EPS Estimate for ADMA Biologics Boosted by Analyst

ADMA Biologics, Inc. (NASDAQ:ADMA) – Investment analysts at Cantor Fitzgerald raised their FY2024 earnings estimates for shares of ADMA Biologics in a report released on Tuesday, January 14th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will earn $0.52 per share for the year, up from their prior forecast of $0.50. Cantor Fitzgerald has a “Overweight” rating and a $20.00 price target on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.52 per share.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the prior year, the business posted $0.01 earnings per share.

A number of other analysts have also commented on ADMA. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Trading Down 1.0 %

NASDAQ ADMA opened at $16.32 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics has a fifty-two week low of $4.82 and a fifty-two week high of $23.64. The stock has a market cap of $3.86 billion, a P/E ratio of 58.29 and a beta of 0.76. The stock has a 50 day simple moving average of $19.29 and a two-hundred day simple moving average of $17.23.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 3.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in ADMA Biologics by 13.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock worth $13,171,000 after acquiring an additional 80,400 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after purchasing an additional 92,281 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of ADMA Biologics in the 3rd quarter worth approximately $61,858,000. EWG Elevate Inc. purchased a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $480,000. Finally, Citigroup Inc. increased its position in ADMA Biologics by 251.7% during the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after buying an additional 277,138 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.